Monte Rosa Therapeutics, Inc. (GLUE)
13.38
-0.94
(-6.56%)
USD |
NASDAQ |
Aug 28, 16:00
13.38
0.00 (0.00%)
After-Hours: 20:00
Monte Rosa Therapeutics Cash from Operations (Quarterly) : -44.11M for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -44.11M |
| March 31, 2026 | -37.37M |
| December 31, 2025 | -43.01M |
| September 30, 2025 | 100.43M |
| June 30, 2025 | -34.72M |
| March 31, 2025 | -45.49M |
| December 31, 2024 | 128.92M |
| September 30, 2024 | -20.99M |
| June 30, 2024 | -27.77M |
| March 31, 2024 | -38.16M |
| December 31, 2023 | 29.63M |
| September 30, 2023 | -24.71M |
| Date | Value |
|---|---|
| June 30, 2023 | -25.32M |
| March 31, 2023 | -23.41M |
| December 31, 2022 | -23.96M |
| September 30, 2022 | -20.60M |
| June 30, 2022 | -20.50M |
| March 31, 2022 | -27.40M |
| December 31, 2021 | -14.17M |
| September 30, 2021 | -17.79M |
| June 30, 2021 | -13.58M |
| March 31, 2021 | -13.82M |
| December 31, 2020 | -8.574M |
| September 30, 2020 | -6.891M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Nurix Therapeutics, Inc. | -96.57M |
| Gilead Sciences, Inc. | 3.573B |
| Ironwood Pharmaceuticals, Inc. | 58.28M |
| Capricor Therapeutics, Inc. | -31.49M |
| Cue Biopharma, Inc. | -29.00M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -28.86M |
| Cash from Financing (Quarterly) | 3.211M |
| Free Cash Flow | -32.08M |
| Free Cash Flow Per Share (Quarterly) | -0.4813 |
| Free Cash Flow to Equity (Quarterly) | -47.76M |
| Free Cash Flow to Firm (Quarterly) | -48.84M |
| Free Cash Flow Yield | -2.75% |